On Nov. 2, 2018, AcelRx pharmaceutical’s DSUVIA was approved by U.S. Food and Drug Administration (FDA). DSUVIA is indicated for the management of acute pain, severe enough to require an opioid analgesic and for which alternative treatments are inadequate, in adults.

The approval comes a year after the initial marketing application for the drug, Dsuvia, was rejected by the FDA, which sought additional safety data and certain changes to ensure that the drug was administered properly.